Zacks Investment Research lowered shares of Arch Therapeutics (OTCMKTS:ARTH) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “
Several other brokerages have also issued reports on ARTH. ValuEngine lowered Arch Therapeutics from a hold rating to a sell rating in a research report on Friday, November 17th. HC Wainwright set a $3.00 price target on Arch Therapeutics and gave the company a buy rating in a report on Tuesday, December 19th. Finally, Ifs Securities upgraded Arch Therapeutics from an outperform rating to a strong-buy rating in a report on Monday, February 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Arch Therapeutics presently has an average rating of Buy and an average target price of $2.17.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3258459/zacks-investment-research-lowers-arch-therapeutics-arth-to-hold-2.html.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.